Join the July 3 2025 Online Course on Sustainable Medical Device Design & Manufacture
Dublin, June 25, 2025 (GLOBE NEWSWIRE) -- The "Sustainable Design and Manufacture for Medical Devices Training Course (ONLINE EVENT: July 3, 2025)" has been added to ResearchAndMarkets.com's offering.
Sustainability in medical technology, as in all industries, is increasingly no longer an option. It's not a question of "if" - it's a question of "how".
This seminar will give you an in depth understanding of what sustainability options exist, what the benefits are, what drives them and how to choose which will work for your company. It will also provide practical advice on how to implement change.
Benefits of attending
Gain an understanding of how sustainability objectives can be made to fit with YOUR organisation and what you should be aiming to achieve
Learn how to assess risk and develop a strategy that delivers worthwhile results in a realistic timeframe
Appreciate where to start, how to manage change and how to justify the investment by measuring improvements
Certifications:
CPD: 6 hours for your records
Certificate of completion
Who Should Attend:
Medical industry leaders
Sustainability leaders
Product owners
Manufacturing managers
Design heads
Business development managers
Anyone interested in sustainable design and manufacture
Course Agenda:
Background
Focus: where does sustainable design and manufacture fit into the overall sustainability picture?
What are the drivers for sustainability in YOUR industry/organisation? What are the barriers?
What has your organisation done so far and why? Did it work? If not, why not?
Understanding how to move forward
Stakeholders in sustainable design and manufacture
Risks - organisational, technical, regulatory and market
Understanding the synergy between design, manufacture and remanufacture
Planning change
Appetite for change - selling the idea, getting stakeholders on board and assessing future market acceptance/demands
Understanding the benefits - how sustainability can add value to your organisation and your products
Sharing the vision and getting commitment/support
Understanding risk - acknowledging that this is new ground and identifying what you don't know you don't know
Planning phased implementation - disruptive change and how to manage it
Feasibility analysis - the answer to the question "should we adopt sustainable manufacture" - might be no!
Implementing change
Where to start - design, manufacture, remanufacture or all three?
How to "do" sustainable design. How have others done it? What can we learn? How suitable is it for medical?
How to implement a recovery and remanufacturing loop. What can we learn from other industries?
What external forces exist and how do we address them?
Where to find support and how to keep the regulators happy
Starting small and working up - balancing risk with manageable rates of progress and measuring success
Scaling up, managing expectations and finding the optimum rate of change
Making the financial case - how does sustainability pay for itself?
Q&A and key takeaways
For more information about this training visit https://www.researchandmarkets.com/r/n5eu4g
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Eating minimally processed meals doubles weight loss even when ultraprocessed foods are healthy, study finds
People in the United Kingdom lost twice as much weight eating meals typically made at home than they did when eating store-bought ultraprocessed food considered healthy, the latest research has found. 'This new study shows that even when an ultraprocessed diet meets nutritional guidelines, people will still lose more weight eating a minimally processed diet,' said coauthor Dr. Kevin Hall, a former senior investigator at the US National Institutes of Health who has conducted some of the world's only controlled clinical trials on ultraprocessed foods. 'This (study) is the largest and longest randomized controlled clinical trial of ultraprocessed foods to date,' Hall added. Hall's past research sequestered healthy volunteers from the world for a month at a time, measuring the impact of ultraprocessed food on their weight, body fat and various biomarkers of health. In a 2019 study, he found people in the United States ate about 500 calories more each day and gained weight when on an ultraprocessed diet than when eating a minimally processed diet matched by calories and nutrients. The weight loss from minimally processed food in the new study was modest — only 2% of the person's baseline weight, said study first author Samuel Dicken, a research fellow at the department of behavioral science and health and the Centre for Obesity Research at University College London. 'Though a 2% reduction may not seem very big, that is only over eight weeks and without people trying to actively reduce their (food) intake,' Dicken said in a statement. 'If we scaled these results up over the course of a year, we'd expect to see a 13% weight reduction in men and a 9% reduction in women.' Men typically have more lean muscle mass than women, which along with testosterone often gives them a quicker boost over women when it comes to weight loss, experts say. Healthier ultraprocessed foods The study, published Monday in the journal Nature Medicine, provided free ultraprocessed or minimally processed meals and snacks to 55 overweight people in the UK for a total of eight weeks. After a short break, the groups switched to the opposite diet for another eight weeks. Study participants were told to eat as much or as little of the 4,000 daily calories as they liked and record their consumption in a diary. By the end of the study, 50 people had spent eight weeks on both diets. While the number of participants may seem small at first glance, providing 16 weeks of food and implementing randomized controlled clinical trials can be costly. For the first eight weeks, 28 people received daily deliveries of minimally processed meals and snacks, such as overnight oats and homemade spaghetti Bolognese. Minimally processed foods, such as fruits, vegetables, meat, milk and eggs, are typically cooked from their natural state, according to NOVA, a recognized system of categorizing foods by their level of processing. Concurrently, another 27 people received a daily delivery of ultraprocessed foods — such as ready-to-eat breakfast bars or heat-and-eat lasagna — for eight weeks. Ultraprocessed foods, or UPFs, contain additives never or rarely used in kitchens and often undergo extensive industrial processing, according to the NOVA classification system. Because ultraprocessed foods are typically high in calories, added sugar, sodium, and saturated fat and low in fiber, they have been linked to weight gain and obesity and the development of chronic conditions including cancer, cardiovascular disease, type 2 diabetes and depression. Such foods may even shorten life. Researchers in this study, however, did something unusual, said Christopher Gardner, Rehnborg Farquhar Professor of Medicine at Stanford University in California who directs the Stanford Prevention Research Center's Nutrition Studies Research Group. 'They tried to make a healthy ultraprocessed diet by picking ultraprocessed foods with the recommended number of fruits, veggies and fiber and lower levels of salt, sugar and saturated fats,' said Gardner, who was not involved in the study. Both the ultraprocessed and the minimally processed meals had to meet the nutritional requirements of the Eatwell Guide, the UK's official government guidance on how to eat a healthy, balanced diet. The United States has similar dietary guidelines, which are used to set federal nutritional standards. 'This is a very solid study, matching dietary interventions for nutrients and food group distribution, while varying only the contribution of ultra-processed foods,' said Dr. David Katz, a specialist in preventive and lifestyle medicine, in an email. Katz, who was not involved in the study, is the founder of the nonprofit True Health Initiative, a global coalition of experts dedicated to evidence-based lifestyle medicine. The lure of ultraprocessed food The study's goal was weight loss, which often comes with improved cardiovascular readings, such as lower blood pressure, cholesterol and blood sugar levels. That happened, but in rather odd and surprising ways, said Marion Nestle, the Paulette Goddard professor emerita of nutrition, food studies and public health at New York University, who was asked to write an editorial to be published with the study. Instead of gaining weight, people on the ultraprocessed diet chose to eat 120 fewer calories a day, thus losing a small amount of weight. People on the minimally processed diet, however, ate 290 fewer calories a day, thus losing even more weight and some body fat as well. 'One possible explanation is that (people on the minimally processed diet) did not like the 'healthy' meals as much as their usual diets,' Nestle, who was not involved in the research, wrote in the editorial. 'They deemed the minimally processed diet less tasty,' Nestle said. 'That diet emphasized 'real' fresh foods, whereas the ultra-processed diet featured commercially packaged 'healthy' ultra-processed food products such as fruit, nut, and protein bars; sandwiches and meals; drinking yoghurts, and plant-based milks.' Less than 1% of people in the UK follow all of the government's nutritional recommendations, according to the study, often choosing ultraprocessed foods as the basis of their normal daily intake. In the US, nearly 60% of an adult's calorie consumption is from ultraprocessed foods. 'People in this study were overweight or obese and were already eating a diet high in all kinds of ultraprocessed foods,' Gardner said. 'So the ultraprocessed diet in the study was healthier than their typical normal diet. Isn't that an odd twist?' People on the minimally processed diet had lower levels of triglycerides, a type of fat in the blood linked to an increased risk of heart disease and stroke, but other markers of heart health didn't vary much between the two diets, according to the study. There was one notable exception: low-density lipoprotein, or LDL, known as 'bad' cholesterol because it can build up in arteries and create blockages to the heart. 'Surprisingly, LDL cholesterol was reduced more on the ultra-processed diet,' said dietitian Dimitrios Koutoukidis, an associate professor of diet, obesity and behavioral sciences at the University of Oxford, who was not involved in the study. 'This might imply that processing is not as important for heart health if the foods already meet the standard UK healthy eating guidance,' Koutoukidis said in a statement. 'Further research is needed to better understand this.' According to Hall, the results fit quite nicely with preliminary results from his current study that is still underway. In that research, Hall and his team measured the impact of four configurations of ultraprocessed foods on the health of 36 volunteers. Each lived for a month in the Metabolic Clinical Research Unit of the National Institutes of Health Clinical Center in Bethesda, Maryland. 'When you modify an ultraprocessed diet to have lower energy (calorie) density and fewer highly palatable foods, you can offset some of the effects of ultraprocessed foods in causing excess calorie intake and weight gain,' Hall said. In other words, choose healthier foods regardless of the levels of processing. 'People don't eat the best ultraprocessed foods, they eat the worst ones, so the take home here is to follow the national guidelines for nutrient quality,' Gardner said. 'Read your nutrient label and choose foods that are low in salt, fat, sugar and calories and high in fiber, and avoid foods with too many additives with unpronounceable names. That's the key to a healthier diet.' Sign up for CNN's Eat, But Better: Mediterranean Style. Our eight-part guide shows you a delicious expert-backed eating lifestyle that will boost your health for life. Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
Organ Care Products Market Valuation Set to Surpass US$ 812.12 Million By 2033
Innovation now defines the organ care products market. Advanced perfusion and portable systems are actively expanding the donor organ pool, tackling immense waiting lists driven by chronic diseases and dramatically improving success rates for vital transplants. Chicago, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The global organ care products market was valued at US$ 199.20 million in 2024 and is expected to reach US$ 812.12 million by 2033, growing at a CAGR of 16.90% during the forecast period 2025–2033. The current scenario in the organ care products market is one of explosive growth, fueled by the twin engines of unprecedented global demand and transformative technology. In 2024, the U.S. performed a record 48,149 transplants, yet this barely meets the need, as regions like Eurotransplant still have over 13,570 patients on waiting lists. This profound supply-demand imbalance is accelerating a fundamental shift away from traditional static cold storage towards advanced perfusion and assessment systems. These technologies are directly addressing the critical issue of organ non-utilization, aiming to convert a portion of the thousands of organs discarded annually into life-saving opportunities, thereby changing the entire calculus of transplantation. Request Sample Pages: This evolution is being aggressively capitalized upon by key industry players through strategic expansion and is buoyed by substantial investment. Recent developments, such as Paragonix's EU MDR certification for five devices in March 2025 and its rapid U.S. commercial expansion, highlight a fierce race to capture market share. The market's momentum is further underwritten by significant capital influx, from government initiatives like the $67 million allocated for U.S. transplant system modernization in FY2025 to targeted research funding from organizations like Enduring Hearts. The current scenario is therefore not just about growth, but about a well-funded, strategic push to commercialize innovation on a global scale. Key Findings in Organ Care Products Market Market Forecast (2033) US$ 812.12 million CAGR 16.90% Largest Region (2024) North America (56%) By Organ Type Kidney (28%) By Product Type Trolly (53%) Top Drivers Rising global incidence of chronic diseases fuels organ transplant demand. Technological advancements in organ preservation systems improve transplant success rates. Favorable reimbursement policies encourage organ transplant procedures, boosting market growth. Top Trends Emergence of normothermic machine perfusion for real-time organ function assessment. Development of smaller, portable organ preservation devices for easier transport. Focus on developing organ-specific preservation solutions for better patient outcomes. Top Challenges Complex ethical and logistical hurdles in organ procurement and allocation. Unprecedented Transplant Volumes Are Fueling Robust Market Expansion and Demand The foundational driver for the organ care products market is the sheer volume of surgical procedures, which continued its upward trajectory through 2024. In the United States alone, a record of over 48,000 organ transplants were performed. This milestone was confirmed with a final tally of 48,149 procedures for the year, marking the first time the nation has exceeded this figure. This represents an impressive average of 132 organ transplants performed each day in the U.S. throughout 2024. Critically, 2024 marked the 14th consecutive year of growth in the number of organs recovered for transplants in the U.S., signaling a sustained and reliable increase in the core activity that underpins the market. This trend is not isolated; globally, organ transplantation activities saw a notable increase in 2023, which has set a strong precedent for continued growth in 2024 and beyond. In Europe, the eight Eurotransplant countries allocated 7,150 organs from deceased donors in 2024, while in China, a remarkable 24,684 transplant surgeries were performed during the same year, showcasing the truly global nature of this expansion. The Critical Role of Organ Procurement in Shaping Market Dynamics The availability and procurement of donor organs represent the starting point for the entire transplantation value chain, directly influencing the organ care products market. In the United States, 55 dedicated organ procurement organizations (OPOs) were operational as of October 2024, forming the backbone of the recovery network. In 2024, these U.S. OPOs successfully recovered over 45,000 organs for transplant procedures. This was made possible by the 16,989 Americans who became deceased organ donors, a testament to growing awareness and consent. These efforts were supplemented by more than 7,000 living donors in the U.S. in 2024. An interesting demographic trend shows that nearly 8,200 of the deceased donors in the U.S. in 2024 were aged 55 and older, highlighting the expanding criteria for donation. In the United Kingdom, from April 2023 to March 2024, there were 1,510 deceased organ donors and 938 living organ donors. Across the Eurotransplant region, organs were sourced from 2,181 deceased donors in 2024. Meanwhile, China recorded 6,744 cases of organ donations in 2024, with the number of registered organ donors soaring to over 7.05 million by early 2025, indicating massive future potential. Organ-Specific Procedural Growth Creates Niche Opportunities Within the Market A deeper analysis of procedural data reveals that growth is not uniform across all organ types, creating distinct and lucrative opportunities within the organ care products market for specialized preservation technologies. In the United States during 2024, cardiac procedures were significant, with 4,572 heart transplants performed. Thoracic procedures were also prominent, as the number of lung transplants reached 3,340. Abdominal transplants, which constitute the largest segment, saw a total of 11,458 liver transplants and an impressive 27,759 kidney transplants performed in the U.S. in 2024. This high volume in renal transplantation underscores the demand for reliable kidney preservation solutions. Furthermore, specialized procedures are gaining traction; in the UK, for instance, 65 Donation after Circulatory Death (DCD) heart transplants took place in the 2023/24 period, a complex procedure that relies heavily on advanced preservation technology to ensure viability. Diverse Regional Landscapes Present Unique Challenges and Growth Avenues The global organ care products market is characterized by significant regional variations in infrastructure, regulatory frameworks, and donation patterns. China's market, for example, is notable for its scale; as of early 2025, there have been more than 58,000 cumulative organ donations to date. The country has also recorded over 63,000 body donations and 110,000 corneal donations as of 2025, pointing to a well-established and growing donation culture. In the UK, the data from 2023-2024 provides a detailed look at the procurement funnel, with 772 donors after brain death (DBD) and 738 donors after circulatory death (DCD). That year, there were 6,794 potential deceased organ donors identified in the UK, of whom 6,421 were formally referred as potential donors. From that pool, donation requests were made to families in 3,107 cases, ultimately resulting in 1,880 consented donors, illustrating the multi-step process where advanced care technology can play a role in boosting confidence and consent. Groundbreaking Product Innovation and Regulatory Wins Propel Market Leaders Forward Innovation is the lifeblood of the organ care products market, with regulatory approvals serving as key milestones that unlock new commercial opportunities. In October 2024, Paragonix Technologies achieved a major milestone with FDA 510(k) clearance for its KidneyVault portable renal perfusion system. This strategic clearance solidified Paragonix as the only company possessing U.S. regulatory clearances for advanced preservation devices for all five solid organs used in transplants. Earlier in the year, in June 2024, the company launched its PancreasPak, the world's first FDA-cleared preservation device for donor pancreases, with pre-orders beginning on June 27, 2024, and full commercial availability planned for September 1, 2024. In April 2024, Paragonix also announced the full U.S. commercial launch of its BAROguard Donor Lung Preservation System. During its limited market release, 5 of the top U.S. thoracic transplant centers had already deployed the BAROguard System. The momentum continued into 2025, when Paragonix received EU MDR approval for five of its organ preservation devices in March. These specific product approvals stood out in a year where the FDA approved a total of just 21 medical devices overall in 2024. Strong Financial Performance and Strategic Investments Signal a Healthy Marketplace The financial health and strategic initiatives of key industry players in the organ care products market provide compelling evidence of a vibrant and growing market. XVIVO Perfusion reported strong results for 2024, with net sales amounting to SEK 822.4 million for the full year. The fourth quarter of 2024 was particularly robust, with net sales reaching SEK 227.6 million. The company's profitability was also solid, with an operating income (EBIT) for Q4 2024 of SEK 15.5 million and an operating income before depreciation and amortization (EBITDA) of SEK 51.9 million. Strong operational execution led to a cash flow from operating activities of SEK 62.1 million in Q4 2024, and the company posted a net profit for the full year 2024 of SEK 172.2 million. On the utilization front, Paragonix preservation devices have been used in over 10,000 transplant cases globally as of March 2025, demonstrating deep market penetration. Specifically, the Paragonix SherpaPak and LUNGguard systems are utilized at over 150 transplant centers globally, including over 40 transplant centers in the EU, highlighting the company's expanding international footprint. Modernization Initiatives and Research Funding Pave the Way for Future Growth Substantial government and institutional investments in research and system modernization are creating a fertile ground for the future growth of the organ care products market. The U.S. Senate Appropriations Committee has included a significant $67 million in funding for the Organ Procurement and Transplantation Network (OPTN) Modernization Initiative for fiscal year 2025. This represents a $13 million increase over FY 2024 levels. The FY24 funding package had already included an additional $23 Million for the HRSA OPTN Modernization Initiative, bringing the total for that year to $52 Million. In 2024, the Mid-America Transplant Foundation's Clinical Innovation Fund began offering awards of up to $150,000 per year for three years to spur new research. The American Society of Transplantation (AST) is furthering this by offering a research grant of $75,000 for one year, with a term starting January 1, 2025. The International Society for Heart & Lung Transplantation is offering a grant of up to $75,000 for research into DCD heart transplantation, with recipients to be announced in January 2025, and a second grant of up to $37,500 for acellular Ex Vivo Lung Perfusion (EVLP) research. In 2024, the Scandiatransplant Research grant also supported two projects with 100,630 DKK and 260,000 DKK, respectively. Need a Customized Version? Request It Now: Addressing Organ Utilization and Waiting Lists Remains a Core Market Imperative The persistent challenges of organ non-utilization and extensive patient waiting lists serve as powerful catalysts for the organ care products market, driving the need for technologies that can preserve, assess, and improve marginal organs. In 2024, a concerning 9,275 recovered kidneys in the U.S. were ultimately not used for transplant, continuing a trend that highlights a critical gap between recovery and utilization. To combat this, OPOs have hosted eleven Transplant Growth Collaborations over the past year to share successful practices. Advanced perfusion is emerging as a key solution; a 2024 study of 803 transplantations, of which 174 received Normothermic Machine Perfusion (NMP), showed NMP was associated with a reduced need for early relaparotomy in liver transplants. Another 2024 study involving 118 NMP-treated livers matched with 236 preserved with static cold storage, and a cohort matching 37 NMP-DCD livers with 74 using static cold storage, are providing crucial data on efficacy. Global Organ Care Products Market Major Players: Bridge to Life Ltd. TransMedics Inc. Organ Recovery system XVIVO Preservation Solution Inc. Paragonix technologies and IGL OrganOx Limited Other Prominent Players Key Market Segmentation: By Organ Type Kidney Liver Heart Lungs Others By Product Type Trolly Portable By Region North America Europe Asia Pacific Middle East Africa South America Request a Personalized Report Walkthrough with Our Research Team: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Kate Middleton Reportedly Sparks Renewed Health Fears 6 Months After Cancer Remission
Kate Middleton's public appearance is once again drawing concern as her noticeably slimmer frame leaves royal watchers uneasy. The future Queen has kept a low profile this summer, surfacing only briefly and looking visibly thinner, even as palace sources insist she is focused on recovery. Kate Middleton initially revealed her cancer diagnosis last year after speculation and conspiracy theories arose from her sudden disappearance from royal duties. Kate Middleton Reportedly Lacks Appetite For Food Those close to the Princess say she is visibly frail, with some estimating her weight has dropped to around 90 pounds. The shift in her appearance has reportedly alarmed even those within royal circles, with sources expressing concern that her body may be struggling to keep up after months of treatment. "Word is she's having a difficult time and has no appetite, and is losing weight as a result. She's gaunt and has little to no muscle tone," one insider said. The concern is not just coming from onlookers. Medical professionals have also weighed in. Speaking to RadarOnline, Dr. Gabe Mirkin suggested that her extreme weight loss could be a sign of ongoing complications. In his words: "This severe weight loss can be caused by the chemotherapy itself, not eating enough because she doesn't feel very well, or treatment failure for her cancer." Inside The Princess Of Wales' Cancer Battle Kate's cancer fight may have been far more severe than the public realized. While she is doing her best to rejoin royal life, sources say she came dangerously close to not making it through. The Blast revealed that behind the scenes, Kate's health crisis was so severe that those close to her now describe her survival as nothing short of "fortunate." Royal commentator Rebecca English reinforced that view, noting that Kate's return to public life is remarkable considering how ill she was just months ago. Another palace source said the experience has been a stark reminder of how long and difficult cancer recovery truly is. "On some levels, I actually think this is a good reminder that she was really seriously ill last year and underwent a significant period of chemo. As anyone who has been through that experience will tell you, you can feel very unwell for a long time afterwards. It can take years to recover," they noted. The Mother-Of-Three Skipped Royal Ascot To Prioritise Her Health, Sources Say While she has made a few appearances in recent months, her absence from the Royal Ascot in June raised questions about the progress of her recovery. Though the high-profile event is a staple on the royal calendar, Kate did not attend. Insiders believe that skipping the event was a conscious choice to prioritize her well-being. Royal experts also pointed out that the intense summer heat in the U.K. may have also influenced her decision. Royal commentator Ingrid Seward shared that Kate is no longer pushing through at any cost. "Her priorities have changed, and she's listening to her body instead of being a people pleaser. She's absolutely got to be strict with herself and say, 'No, I can't do this,'" Seward said. Kate Made A Radiant Return At Wimbledon Amid Her Recovery Still, despite the physical and emotional strain, Kate has tried to show up where she can. She made a rare but powerful public appearance at Wimbledon last month, amid her continuing recovery. The Blast highlighted her arrival at Centre Court, where she was joined by her daughter Princess Charlotte and sister Pippa. The crowd greeted her with a standing ovation as she entered the royal box. As patron of the All England Lawn Tennis and Croquet Club, Kate returned to familiar ground, this time to present the trophy at the women's final between Amanda Anisimova and Iga Swiatek. Wearing a cream skirt and white belted blazer, she kept her look polished. Her minimal makeup and softly styled hair added to her quiet confidence. Kate Middleton Curates Personal Art Display At V&A Museum Although she missed the Ascot in June, the 43-year-old put her art history background to use as a guest curator that same month. PEOPLE shared that Kate selected a group of objects for a display at the V&A East Storehouse. Titled "Makers and Creators," the collection reflects her personal taste and ties to the arts, built in collaboration with the museum's curatorial team. Her picks range from ballet costumes to vintage keepsakes. A standout item is a costume designed by Oliver Messel for "The Sleeping Beauty," once worn in a Royal Ballet performance back in 1960. The display also includes a hand-quilted Welsh bedcover from the 1800s and a forest-themed watercolor by Peter Rabbit creator Beatrix Potter, along with a childhood photo album belonging to Potter's father. Will Kate Middleton or the Royal family address the health concerns? Solve the daily Crossword
